Genitourinary Cancer

Darolutamide Postpones Need For Procedure, Slows Down Quality of Life Deterioration in Patients with nmCRPC

September 13, 2021

Researchers identified a slower rate of health-related quality of life deterioration, as well as an ability to postpone locally invasive procedures, in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

FDA OKs Adjuvant Nivolumab to Treat High-Risk Urothelial Carcinoma

August 20, 2021

The Food and Drug Administration approved adjuvant nivolumab to treat urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.